286 related articles for article (PubMed ID: 26667094)
1. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
Su SC; Lin CW; Yang WE; Fan WL; Yang SF
Expert Opin Ther Targets; 2016; 20(5):551-66. PubMed ID: 26667094
[TBL] [Abstract][Full Text] [Related]
2. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
3. The urokinase plasminogen activator system: role in malignancy.
Duffy MJ
Curr Pharm Des; 2004; 10(1):39-49. PubMed ID: 14754404
[TBL] [Abstract][Full Text] [Related]
4. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
6. The urokinase plasminogen activator system: a target for anti-cancer therapy.
Ulisse S; Baldini E; Sorrenti S; D'Armiento M
Curr Cancer Drug Targets; 2009 Feb; 9(1):32-71. PubMed ID: 19200050
[TBL] [Abstract][Full Text] [Related]
7. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract][Full Text] [Related]
8. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
11. The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role.
Madunić J
Thromb Haemost; 2018 Dec; 118(12):2020-2036. PubMed ID: 30419600
[TBL] [Abstract][Full Text] [Related]
12. Modulators of the urokinase-type plasminogen activation system for cancer.
Hildenbrand R; Allgayer H; Marx A; Stroebel P
Expert Opin Investig Drugs; 2010 May; 19(5):641-52. PubMed ID: 20402599
[TBL] [Abstract][Full Text] [Related]
13. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
15. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
18. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
20. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]